Pleuroparenchymal Fibroelastosis as a Late-Onset Pulmonary Toxicity after Treatment with Anticancer Chemotherapy for High-Risk Neuroblastoma

Pleuroparenchymal Fibroelastosis as a Late-Onset Pulmonary Toxicity after Treatment with Anticancer Chemotherapy for High-Risk Neuroblastoma

Pleuroparenchymal fibroelastosis (PPFE) is a rare, progressive, restrictive lung disease characterized by hypercarbic respiratory failure. In pediatrics, it has been described in patients with a history of malignancy who have received a bone marrow transplant, chemotherapy, or radiotherapy. It is ch...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Case reports in pediatrics 2024, Vol.2024, p.4352032-4352032
Hauptverfasser: Yokoyama, Satoshi, Kanai, Risa, Fukao, Daisuke, Hamahata, Keigo
Format: Report
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4352032
container_issue
container_start_page 4352032
container_title Case reports in pediatrics
container_volume 2024
creator Yokoyama, Satoshi
Kanai, Risa
Fukao, Daisuke
Hamahata, Keigo
description Pleuroparenchymal fibroelastosis (PPFE) is a rare, progressive, restrictive lung disease characterized by hypercarbic respiratory failure. In pediatrics, it has been described in patients with a history of malignancy who have received a bone marrow transplant, chemotherapy, or radiotherapy. It is characterized by pleural thickening, fibrosis, subpleural elastosis, and intraalveolar collagen deposits. Survival is poor, and the only therapy is lung transplantation. Here, we report a patient who developed PPFE as a late-onset pulmonary toxicity after treatment with anticancer chemotherapy for high-risk neuroblastoma (NB).
doi_str_mv 10.1155/2024/4352032
format Report
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_3060747118</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3060747118</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_30607471183</originalsourceid><addsrcrecordid>eNqVj81KA0EQhOegYNDcfIA-elkzM_uTeJRgyEFMkL2HztKbnTg_6_Qsuu_gQ7uKL2BRUIcq-CghbpW8V6osF1rqYlHkpZa5vhAzLR9kVq1kfiXmzGc5qZJaVXomvvaWhhh6jOSbbnRoYWOOMZBFToENA06GZ0yU7TxTgv1gXfAYR6jDp2lMGgHbRBHqSJgc-QQfJnXw6JNp0DdTs-7IhdRRxH6ENkTYmlOXvRp-g5cf-vEX5vBGXLZomeZ_eS3uNk_1epv1MbwPxOngDDdkLXoKAx_y6cayWCq1yv8x_QYlYl5W</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype><pqid>3060747118</pqid></control><display><type>report</type><title>Pleuroparenchymal Fibroelastosis as a Late-Onset Pulmonary Toxicity after Treatment with Anticancer Chemotherapy for High-Risk Neuroblastoma</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Wiley-Blackwell Open Access Titles</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Yokoyama, Satoshi ; Kanai, Risa ; Fukao, Daisuke ; Hamahata, Keigo</creator><creatorcontrib>Yokoyama, Satoshi ; Kanai, Risa ; Fukao, Daisuke ; Hamahata, Keigo</creatorcontrib><description>Pleuroparenchymal fibroelastosis (PPFE) is a rare, progressive, restrictive lung disease characterized by hypercarbic respiratory failure. In pediatrics, it has been described in patients with a history of malignancy who have received a bone marrow transplant, chemotherapy, or radiotherapy. It is characterized by pleural thickening, fibrosis, subpleural elastosis, and intraalveolar collagen deposits. Survival is poor, and the only therapy is lung transplantation. Here, we report a patient who developed PPFE as a late-onset pulmonary toxicity after treatment with anticancer chemotherapy for high-risk neuroblastoma (NB).</description><identifier>ISSN: 2090-6803</identifier><identifier>DOI: 10.1155/2024/4352032</identifier><language>eng</language><ispartof>Case reports in pediatrics, 2024, Vol.2024, p.4352032-4352032</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784,864,4490,27925</link.rule.ids></links><search><creatorcontrib>Yokoyama, Satoshi</creatorcontrib><creatorcontrib>Kanai, Risa</creatorcontrib><creatorcontrib>Fukao, Daisuke</creatorcontrib><creatorcontrib>Hamahata, Keigo</creatorcontrib><title>Pleuroparenchymal Fibroelastosis as a Late-Onset Pulmonary Toxicity after Treatment with Anticancer Chemotherapy for High-Risk Neuroblastoma</title><title>Case reports in pediatrics</title><description>Pleuroparenchymal fibroelastosis (PPFE) is a rare, progressive, restrictive lung disease characterized by hypercarbic respiratory failure. In pediatrics, it has been described in patients with a history of malignancy who have received a bone marrow transplant, chemotherapy, or radiotherapy. It is characterized by pleural thickening, fibrosis, subpleural elastosis, and intraalveolar collagen deposits. Survival is poor, and the only therapy is lung transplantation. Here, we report a patient who developed PPFE as a late-onset pulmonary toxicity after treatment with anticancer chemotherapy for high-risk neuroblastoma (NB).</description><issn>2090-6803</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2024</creationdate><recordtype>report</recordtype><recordid>eNqVj81KA0EQhOegYNDcfIA-elkzM_uTeJRgyEFMkL2HztKbnTg_6_Qsuu_gQ7uKL2BRUIcq-CghbpW8V6osF1rqYlHkpZa5vhAzLR9kVq1kfiXmzGc5qZJaVXomvvaWhhh6jOSbbnRoYWOOMZBFToENA06GZ0yU7TxTgv1gXfAYR6jDp2lMGgHbRBHqSJgc-QQfJnXw6JNp0DdTs-7IhdRRxH6ENkTYmlOXvRp-g5cf-vEX5vBGXLZomeZ_eS3uNk_1epv1MbwPxOngDDdkLXoKAx_y6cayWCq1yv8x_QYlYl5W</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Yokoyama, Satoshi</creator><creator>Kanai, Risa</creator><creator>Fukao, Daisuke</creator><creator>Hamahata, Keigo</creator><scope>7X8</scope></search><sort><creationdate>20240101</creationdate><title>Pleuroparenchymal Fibroelastosis as a Late-Onset Pulmonary Toxicity after Treatment with Anticancer Chemotherapy for High-Risk Neuroblastoma</title><author>Yokoyama, Satoshi ; Kanai, Risa ; Fukao, Daisuke ; Hamahata, Keigo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_30607471183</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Yokoyama, Satoshi</creatorcontrib><creatorcontrib>Kanai, Risa</creatorcontrib><creatorcontrib>Fukao, Daisuke</creatorcontrib><creatorcontrib>Hamahata, Keigo</creatorcontrib><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yokoyama, Satoshi</au><au>Kanai, Risa</au><au>Fukao, Daisuke</au><au>Hamahata, Keigo</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Pleuroparenchymal Fibroelastosis as a Late-Onset Pulmonary Toxicity after Treatment with Anticancer Chemotherapy for High-Risk Neuroblastoma</atitle><jtitle>Case reports in pediatrics</jtitle><date>2024-01-01</date><risdate>2024</risdate><volume>2024</volume><spage>4352032</spage><epage>4352032</epage><pages>4352032-4352032</pages><issn>2090-6803</issn><abstract>Pleuroparenchymal fibroelastosis (PPFE) is a rare, progressive, restrictive lung disease characterized by hypercarbic respiratory failure. In pediatrics, it has been described in patients with a history of malignancy who have received a bone marrow transplant, chemotherapy, or radiotherapy. It is characterized by pleural thickening, fibrosis, subpleural elastosis, and intraalveolar collagen deposits. Survival is poor, and the only therapy is lung transplantation. Here, we report a patient who developed PPFE as a late-onset pulmonary toxicity after treatment with anticancer chemotherapy for high-risk neuroblastoma (NB).</abstract><doi>10.1155/2024/4352032</doi></addata></record>
fulltext fulltext
identifier ISSN: 2090-6803
ispartof Case reports in pediatrics, 2024, Vol.2024, p.4352032-4352032
issn 2090-6803
language eng
recordid cdi_proquest_miscellaneous_3060747118
source DOAJ Directory of Open Access Journals; PubMed Central Open Access; Wiley-Blackwell Open Access Titles; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
title Pleuroparenchymal Fibroelastosis as a Late-Onset Pulmonary Toxicity after Treatment with Anticancer Chemotherapy for High-Risk Neuroblastoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T00%3A58%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Pleuroparenchymal%20Fibroelastosis%20as%20a%20Late-Onset%20Pulmonary%20Toxicity%20after%20Treatment%20with%20Anticancer%20Chemotherapy%20for%20High-Risk%20Neuroblastoma&rft.jtitle=Case%20reports%20in%20pediatrics&rft.au=Yokoyama,%20Satoshi&rft.date=2024-01-01&rft.volume=2024&rft.spage=4352032&rft.epage=4352032&rft.pages=4352032-4352032&rft.issn=2090-6803&rft_id=info:doi/10.1155/2024/4352032&rft_dat=%3Cproquest%3E3060747118%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3060747118&rft_id=info:pmid/&rfr_iscdi=true